Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652095 | 0.86 | ACHE (0.39) | HRH3KCNH2CYP2D6HTR4 | |
| SCHEMBL19652110 | 0.82 | NCF1 (0.38) | CYP2D6DPP4DPP8DPP9DPP7 | |
| SCHEMBL13212857 | 0.82 | HRH3 (0.38) | HRH3KCNH2CYP2D6DPP4KDM4E | |
| SCHEMBL25564696 | 0.81 | ALOX5 (0.39) | CYP2D6DPP4DPP8DPP9DPP7 | |
| SCHEMBL19652132 | 0.81 | BCHE (0.36) | CYP2D6DPP4DPP8DPP9DPP7 | |
| SCHEMBL23560054 | 0.79 | SMN1; SMN2 (0.42) | CYP2D6DPP4DPP8DPP9DPP7 | |
| SCHEMBL17471145 | 0.79 | HRH3 (0.57) | HRH3KCNH2CYP2D6 | |
| SCHEMBL19652102 | 0.78 | SIGMAR1 (0.36) | HRH3CYP2D6DPP4DPP8DPP9 | |
| SCHEMBL19652167 | 0.76 | ACHE (0.44) | HTR4SIGMAR1 | |
| SCHEMBL16083492 | 0.76 | ALDH1A1 (0.41) | HRH3KCNH2CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | HRH3 131/4885KCNH2 3447/4885CYP2D6 3694/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | HRH3 131/4885KCNH2 3447/4885CYP2D6 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.